These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22647713)

  • 1. LRRK2 knockout mice have an intact dopaminergic system but display alterations in exploratory and motor co-ordination behaviors.
    Hinkle KM; Yue M; Behrouz B; Dächsel JC; Lincoln SJ; Bowles EE; Beevers JE; Dugger B; Winner B; Prots I; Kent CB; Nishioka K; Lin WL; Dickson DW; Janus CJ; Farrer MJ; Melrose HL
    Mol Neurodegener; 2012 May; 7():25. PubMed ID: 22647713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic analysis of Parkinson's disease-linked leucine-rich repeat kinase 2.
    Tong Y; Shen J
    Biochem Soc Trans; 2012 Oct; 40(5):1042-6. PubMed ID: 22988862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway.
    Tong Y; Giaime E; Yamaguchi H; Ichimura T; Liu Y; Si H; Cai H; Bonventre JV; Shen J
    Mol Neurodegener; 2012 Jan; 7():2. PubMed ID: 22230652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice.
    Yue M; Hinkle KM; Davies P; Trushina E; Fiesel FC; Christenson TA; Schroeder AS; Zhang L; Bowles E; Behrouz B; Lincoln SJ; Beevers JE; Milnerwood AJ; Kurti A; McLean PJ; Fryer JD; Springer W; Dickson DW; Farrer MJ; Melrose HL
    Neurobiol Dis; 2015 Jun; 78():172-95. PubMed ID: 25836420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic and acute LRRK2 silencing has no long-term behavioral effects, whereas wild-type and mutant LRRK2 overexpression induce motor and cognitive deficits and altered regulation of dopamine release.
    Volta M; Cataldi S; Beccano-Kelly D; Munsie L; Tatarnikov I; Chou P; Bergeron S; Mitchell E; Lim R; Khinda J; Lloret A; Bennett CF; Paradiso C; Morari M; Farrer MJ; Milnerwood AJ
    Parkinsonism Relat Disord; 2015 Oct; 21(10):1156-63. PubMed ID: 26282470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake.
    Zhou H; Huang C; Tong J; Hong WC; Liu YJ; Xia XG
    Int J Biol Sci; 2011; 7(6):753-61. PubMed ID: 21698001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Altered Development of Synapse Structure and Function in Striatum Caused by Parkinson's Disease-Linked LRRK2-G2019S Mutation.
    Matikainen-Ankney BA; Kezunovic N; Mesias RE; Tian Y; Williams FM; Huntley GW; Benson DL
    J Neurosci; 2016 Jul; 36(27):7128-41. PubMed ID: 27383589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S.
    Li X; Patel JC; Wang J; Avshalumov MV; Nicholson C; Buxbaum JD; Elder GA; Rice ME; Yue Z
    J Neurosci; 2010 Feb; 30(5):1788-97. PubMed ID: 20130188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Behavioral deficits and striatal DA signaling in LRRK2 p.G2019S transgenic rats: a multimodal investigation including PET neuroimaging.
    Walker MD; Volta M; Cataldi S; Dinelle K; Beccano-Kelly D; Munsie L; Kornelsen R; Mah C; Chou P; Co K; Khinda J; Mroczek M; Bergeron S; Yu K; Cao LP; Funk N; Ott T; Galter D; Riess O; Biskup S; Milnerwood AJ; Stoessl AJ; Farrer MJ; Sossi V
    J Parkinsons Dis; 2014; 4(3):483-98. PubMed ID: 25000966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice.
    Tong Y; Yamaguchi H; Giaime E; Boyle S; Kopan R; Kelleher RJ; Shen J
    Proc Natl Acad Sci U S A; 2010 May; 107(21):9879-84. PubMed ID: 20457918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Motor Impairments and Dopaminergic Defects Caused by Loss of Leucine-Rich Repeat Kinase Function in Mice.
    Huang G; Bloodgood DW; Kang J; Shahapal A; Chen P; Kaganovsky K; Kim JI; Ding JB; Shen J
    J Neurosci; 2022 Jun; 42(23):4755-4765. PubMed ID: 35534227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2.
    Ramonet D; Daher JP; Lin BM; Stafa K; Kim J; Banerjee R; Westerlund M; Pletnikova O; Glauser L; Yang L; Liu Y; Swing DA; Beal MF; Troncoso JC; McCaffery JM; Jenkins NA; Copeland NG; Galter D; Thomas B; Lee MK; Dawson TM; Dawson VL; Moore DJ
    PLoS One; 2011 Apr; 6(4):e18568. PubMed ID: 21494637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights into LRRK2 function and dysfunction from transgenic and knockout rodent models.
    Sloan M; Alegre-Abarrategui J; Wade-Martins R
    Biochem Soc Trans; 2012 Oct; 40(5):1080-5. PubMed ID: 22988869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 overexpression alters glutamatergic presynaptic plasticity, striatal dopamine tone, postsynaptic signal transduction, motor activity and memory.
    Beccano-Kelly DA; Volta M; Munsie LN; Paschall SA; Tatarnikov I; Co K; Chou P; Cao LP; Bergeron S; Mitchell E; Han H; Melrose HL; Tapia L; Raymond LA; Farrer MJ; Milnerwood AJ
    Hum Mol Genet; 2015 Mar; 24(5):1336-49. PubMed ID: 25343991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.
    Maekawa T; Mori S; Sasaki Y; Miyajima T; Azuma S; Ohta E; Obata F
    Mol Neurodegener; 2012 Apr; 7():15. PubMed ID: 22534020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenic LRRK2 variants are gain-of-function mutations that enhance LRRK2-mediated repression of β-catenin signaling.
    Berwick DC; Javaheri B; Wetzel A; Hopkinson M; Nixon-Abell J; Grannò S; Pitsillides AA; Harvey K
    Mol Neurodegener; 2017 Jan; 12(1):9. PubMed ID: 28103901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The parkinson's disease-associated LRRK2 mutation R1441G inhibits neuronal differentiation of neural stem cells.
    Bahnassawy L; Nicklas S; Palm T; Menzl I; Birzele F; Gillardon F; Schwamborn JC
    Stem Cells Dev; 2013 Sep; 22(18):2487-96. PubMed ID: 23600457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (G2019S) LRRK2 causes early-phase dysfunction of SNpc dopaminergic neurons and impairment of corticostriatal long-term depression in the PD transgenic mouse.
    Chou JS; Chen CY; Chen YL; Weng YH; Yeh TH; Lu CS; Chang YM; Wang HL
    Neurobiol Dis; 2014 Aug; 68():190-9. PubMed ID: 24830390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells.
    Plowey ED; Cherra SJ; Liu YJ; Chu CT
    J Neurochem; 2008 May; 105(3):1048-56. PubMed ID: 18182054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-dependent accumulation of oligomeric SNCA/α-synuclein from impaired degradation in mutant LRRK2 knockin mouse model of Parkinson disease: role for therapeutic activation of chaperone-mediated autophagy (CMA).
    Ho PW; Leung CT; Liu H; Pang SY; Lam CS; Xian J; Li L; Kung MH; Ramsden DB; Ho SL
    Autophagy; 2020 Feb; 16(2):347-370. PubMed ID: 30983487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.